Back to Search
Start Over
Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in individuals with prediabetes and obesity or overweight from the SCALE Obesity and prediabetes randomised, double-blind, placebo-controlled trial.
- Source :
- Obesity Research & Clinical Practice; Jan2019, Vol. 13 Issue 1, p99-99, 1p
- Publication Year :
- 2019
- Subjects :
- TYPE 2 diabetes diagnosis
TYPE 2 diabetes prevention
TYPE 2 diabetes risk factors
TYPE 2 diabetes treatment
OBESITY treatment
CONFIDENCE intervals
EXERCISE
EXERCISE therapy
PANCREATITIS
PATIENT monitoring
PREDIABETIC state
WEIGHT loss
BODY mass index
RANDOMIZED controlled trials
TREATMENT effectiveness
BLIND experiment
HYPODERMOCLYSIS
KAPLAN-Meier estimator
GLUCAGON-like peptide-1 agonists
ODDS ratio
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 1871403X
- Volume :
- 13
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Obesity Research & Clinical Practice
- Publication Type :
- Academic Journal
- Accession number :
- 134595966
- Full Text :
- https://doi.org/10.1016/j.orcp.2016.10.259